Roche CEO laments Swiss franc strength, continues U.S. investment
Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker. First-quarter sales came in at 14.7 billion Swiss francs ($18.7 billion), down 5% year-on-year — but up 6% on a constant currency basis….